The GLP-1 Monthly Bill: Compounded and Brand, Itemized

Some links on our site may earn us a commission at no extra cost to you. Learn more.

Updated August 2026: rebuilt as a line-item cost ledger with current self-pay pricing verified directly from Novo Nordisk’s and Eli Lilly’s own direct-to-consumer pharmacy programs, and updated to reflect the FDA’s 2025–2026 narrowing of compounded GLP-1 availability. This update also removed pricing citations tied to any single named compounded telehealth provider, in favor of publicly advertised market-rate ranges, so nothing in this article reads as a claim about any specific company’s legal compliance.

Medical Disclaimer: We are not doctors, pharmacists, or medical professionals, and nothing in this comparison is medical advice. This is independent editorial content for informational purposes only. GLP-1 medications are prescription-only — a licensed clinician determines eligibility and which medication, if any, is appropriate. Compounded medications are not FDA-approved, and as of 2026 their availability is legally narrower than it was in 2023–2024. Individual results vary, and weight loss is never guaranteed.

Forget the headline number you’ve seen elsewhere. The real GLP-1 bill isn’t one price — it’s a running ledger of line items that add up differently depending on which path you take, and that ledger has changed significantly in the past year now that Novo Nordisk and Eli Lilly both sell directly to self-pay patients. We itemized every real cost, verified current pricing straight from the manufacturers’ own pharmacy programs, and tallied what a full year actually runs.

Line item 1: Getting started

Brand-name and compounded paths both start with a prescriber sign-off — no path skips this step. Many compounded telehealth platforms fold the intake consultation into their flat monthly price — a bundled fee covering consultation, medication, supplies, shipping, and monitoring commonly runs $199–$349/month, per publicly advertised rates across several such platforms. Going the brand-name route through your own doctor or an existing insurance relationship may mean a separate office-visit cost outside this ledger; going through a manufacturer’s own telehealth partners (NovoCare Pharmacy lists Costco, GoodRx, WeightWatchers, Ro, LifeMD, and eMed among its partners) usually rolls the consult into that partner’s own program fee.

Line item 2: The medication itself — this is where the ledger gets interesting

Both semaglutide and tirzepatide are FDA-labeled as once-weekly injections, so a 28-day supply is four doses — that’s the basis for the per-dose math below. As of August 2026, verified directly from each manufacturer’s own direct-to-consumer pharmacy site: Novo Nordisk’s NovoCare Pharmacy prices self-pay Wegovy at an ongoing standard rate of $349/month for its starting doses (0.25mg–0.5mg), which works out to $349 ÷ 4 = $87.25 per weekly dose. Eli Lilly’s LillyDirect prices self-pay Zepbound vials starting at $299/month for the 2.5mg starting dose ($74.75/dose) and $449/month for maintenance doses (5mg–15mg) through its Journey Program refill timing ($112.25/dose). Compare that to advertised compounded pricing at telehealth platforms in this space, which commonly runs $199/month for semaglutide ($49.75/dose) and $349/month for tirzepatide ($87.25/dose), both typically flat regardless of dose.

The headline takeaway: the gap has narrowed a lot. For semaglutide, compounded still runs roughly half of brand-name self-pay ($199 vs. $349/month). For tirzepatide, the gap has nearly closed — a typical flat compounded rate of $349/month sits close to Zepbound’s own $299–$449 self-pay tiers, a very different picture than the $150-vs-$1,349 framing that circulated when these comparisons were first written, before either manufacturer opened a direct-to-consumer self-pay pharmacy.

Line item 3: Supplies

Brand-name pens (the standard Wegovy and Ozempic delivery device) are pre-filled and need no separate needle purchase. Zepbound and vial-based compounded products both require separate syringes, alcohol swabs, and sharps disposal unless the provider bundles them — many flat-fee compounded programs include supplies in their price; a self-supplied vial route can run an additional $10–$20/month at a pharmacy.

Line item 4: Staying on it — monitoring and follow-up

Ongoing check-ins, dose-adjustment reviews, and any lab work your clinician orders are a real recurring cost on either path. Compounded telehealth subscriptions typically bundle basic monitoring into the flat monthly fee; brand-name self-pay through NovoCare or LillyDirect still requires a prescribing relationship with a clinician, whose own visit or telehealth-partner fee sits outside the pharmacy price quoted above — budget for it separately rather than assuming the medication price is the whole bill.

Line item 5: The regulatory line item nobody prices — but should

This is the line item that makes compounded GLP-1s different from a normal generic-drug cost comparison. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025 — the shortage-based exception that let compounding pharmacies mass-produce copies of these drugs during 2022–2024 no longer broadly applies. As of April 1, 2026, the FDA states it will take enforcement action against compounders producing “essentially copies” of commercially available semaglutide or tirzepatide “regularly or in inordinate amounts,” with a narrow carve-out for pharmacies filling four or fewer prescriptions of a given compounded product per month, or documenting a genuine personalized-dose need a commercial product can’t meet. On April 30, 2026, the FDA went further, proposing to permanently exclude semaglutide, tirzepatide, and liraglutide from the list that allows large-scale 503B outsourcing facilities to compound them at all — a proposal that, if finalized, would close that door even if a future shortage occurred. The FDA has also linked compounded semaglutide to more than 455 adverse event reports, many involving dosing errors from self-administered multi-dose vials.

None of this means every compounded product on the market today is unsafe or illegal — 503A pharmacies can still legally compound personalized, non-standard doses for a documented individual medical need. But it does mean the wide-open “cheap copy of the brand drug for anyone who wants one” version of the compounded market that existed in 2023–2024 is legally narrower now, and getting narrower. This article does not evaluate or make any claim about any specific compounded telehealth provider’s compliance status — if you’re considering a compounded option, ask the specific platform directly how it stays compliant with the post-shortage rules, and confirm the dispensing pharmacy’s state license before paying anything.

Line item 6: Dose escalation — the bill often rises before it stabilizes

Both drug classes are typically titrated upward over several months rather than started at a maintenance dose, and on the brand-name side, LillyDirect’s own published tiers show the bill rising in step: $299/month at the 2.5mg starting dose, $399/month at 5mg, then $449/month at 7.5mg and above under its Journey Program refill timing (or $499–$699/month at those same doses without it). A patient titrating from 2.5mg through a 7.5mg maintenance dose over their first year would pay roughly $299 (month 1) + $399 (month 2) + $449 × 10 (months 3–12) = $5,188 for that first year — noticeably more than a flat monthly rate suggests. Compounded pricing at flat-fee telehealth platforms is often flat regardless of dose, which trades a lower ceiling for less predictability about what any given month costs on the brand side.

The full-year ledger

Here’s what a full year actually costs at the medication line alone (supplies, consults, and monitoring vary too much by provider to total honestly — see the line items above for those separately):

Prices are approximate, current as of publication, and change frequently — confirm the latest price directly with NovoCare Pharmacy, LillyDirect, or your chosen compounded telehealth provider before budgeting.

The verdict

Brand-name self-pay fits you if you want an FDA-approved finished product and can absorb roughly $4,200–$5,200 a year — a real cost, but far closer to compounded pricing than it used to be now that both manufacturers sell direct. Compounded fits you if the brand-name price is still out of reach and you do the vetting: confirm the specific pharmacy you’re considering is licensed, ask specifically how they’re complying with the FDA’s post-shortage compounding rules, and get a plain answer on FDA status before paying anything. Skip both if a licensed clinician hasn’t evaluated whether GLP-1 treatment is appropriate for you — that’s the gate everything else in this ledger waits behind.

How we compared

Every brand-name price in this ledger was pulled directly from Novo Nordisk’s NovoCare Pharmacy site and Eli Lilly’s LillyDirect site, plus Novo Nordisk’s own November 2025 press release announcing its current self-pay pricing structure. Compounded pricing reflects commonly advertised rates across several compounded telehealth platforms, current as of this writing; we deliberately did not build this comparison around any single named compounded provider, since pricing and legal compliance vary by provider and change as FDA rules evolve — always verify a specific provider’s current pricing and licensing status directly before choosing one, rather than relying on any one article. Regulatory details come from the FDA’s own published statements and reporting from Pharmacy Times. No medication on this page was tested by our team, and nothing here substitutes for a licensed clinician’s guidance, consistent with our editorial standards.

Frequently asked questions

Why is compounded still legal if the FDA shortage is over?
Because the legal basis narrowed rather than disappeared — 503A pharmacies can still compound personalized, non-standard doses for a documented individual medical need; what’s no longer broadly permitted is mass-producing exact copies of the commercial product for anyone who orders one.

Is the price gap between compounded and brand-name still worth it?
It’s much smaller than it used to be. As of this ledger, compounded semaglutide runs about half of brand-name self-pay pricing, while compounded tirzepatide is now within roughly 20% of Zepbound’s own direct-to-consumer price — worth weighing against the regulatory narrowing above, not treated as a simple discount with no other differences.

Does insurance change this math?
Often significantly — a commercial-insurance manufacturer savings card can bring brand-name Wegovy or Zepbound down to a small fraction of the self-pay prices in this ledger for eligible patients. This ledger covers cash self-pay specifically because that’s the price point compounded options compete on; check your own coverage before assuming either self-pay number applies to you.

Ready to compare actual telehealth programs on service and support rather than just the medication line? Start with our GLP-1 telehealth head-to-head.